bempedoic acid + ezetimibe + atorvastatin

**Bempedoic acid + ezetimibe + atorvastatin** is a triple combination therapy of lipid-lowering agents used to treat hypercholesterolemia, particularly in patients at high or very high cardiovascular risk, including those with partial statin intolerance[1][5]. - **Bempedoic acid** inhibits ATP citrate lyase, reducing cholesterol synthesis in the liver. - **Ezetimibe** inhibits the Niemann-Pick C1-Like 1 (NPC1L1) protein, blocking intestinal cholesterol absorption. - **Atorvastatin** is an HMG-CoA reductase inhibitor (statin) that reduces cholesterol biosynthesis in hepatocytes. Together, these agents act synergistically, significantly reducing LDL-cholesterol and other atherogenic lipids. The combination allows most patients to reach recommended LDL-C targets and may reduce the risk of cardiovascular events[1][5]. This regimen is particularly considered for patients who require intensive LDL-C lowering or have statin intolerance but can tolerate a partial statin dose[5]. Developed and trialed as a combination, especially by Esperion Therapeutics, clinical studies show its safety and efficacy for short-term use in adults with high cholesterol[1].

Other names

Atorvastatin/Ezetimibe/Bempedoic AcidAtorvastatin/Ezetimibe/Bempedoic Acid 180/10/40Atorvastatin/Ezetimibe/Bempedoic Acid 180/10/20Atorvastatin/Ezetimibe/Bempedoic Acid 180/10/10